Aligos Therapeutics (ALGS) Competitors $10.22 +0.15 (+1.49%) Closing price 04:00 PM EasternExtended Trading$9.97 -0.25 (-2.44%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. RNAC, TLSA, SGMT, AVIR, VOR, OGI, PRQR, HRTX, TRDA, and CABAShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Cartesian Therapeutics (RNAC), Tiziana Life Sciences (TLSA), Sagimet Biosciences (SGMT), Atea Pharmaceuticals (AVIR), Vor Biopharma (VOR), Organigram Global (OGI), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Cartesian Therapeutics Tiziana Life Sciences Sagimet Biosciences Atea Pharmaceuticals Vor Biopharma Organigram Global ProQR Therapeutics Heron Therapeutics Entrada Therapeutics Cabaletta Bio Cartesian Therapeutics (NASDAQ:RNAC) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Do institutionals & insiders believe in RNAC or ALGS? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer RNAC or ALGS? In the previous week, Cartesian Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for Aligos Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.78 beat Aligos Therapeutics' score of 0.75 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, RNAC or ALGS? Cartesian Therapeutics has higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M6.68-$77.42M-$52.83-0.19Aligos Therapeutics$3.94M15.95-$131.21M-$19.79-0.52 Do analysts prefer RNAC or ALGS? Cartesian Therapeutics currently has a consensus target price of $40.00, indicating a potential upside of 300.00%. Aligos Therapeutics has a consensus target price of $50.00, indicating a potential upside of 389.24%. Given Aligos Therapeutics' higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, RNAC or ALGS? Cartesian Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Is RNAC or ALGS more profitable? Cartesian Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Cartesian Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% Aligos Therapeutics -2,337.24%-22.41%-12.09% SummaryCartesian Therapeutics beats Aligos Therapeutics on 12 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.94M$3.36B$6.16B$10.57BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-0.5222.0285.5827.12Price / Sales15.95463.22612.62135.31Price / CashN/A46.3226.3031.10Price / Book-1.369.9612.876.67Net Income-$131.21M-$52.42M$3.30B$276.23M7 Day Performance6.24%5.95%4.80%3.31%1 Month Performance-9.88%11.59%8.11%10.76%1 Year Performance25.25%25.01%75.85%33.58% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.9707 of 5 stars$10.22+1.5%$50.00+389.2%+23.4%$61.94M$3.94M-0.5290RNACCartesian Therapeutics2.1858 of 5 stars$9.85+6.4%$40.00+306.1%-58.4%$240.78M$38.91M-0.1964High Trading VolumeTLSATiziana Life Sciences0.508 of 5 stars$2.13+3.4%N/A+97.0%$240.71MN/A0.008Upcoming EarningsSGMTSagimet Biosciences2.8489 of 5 stars$6.92-5.7%$25.67+270.9%+78.2%$238.71M$2M-3.788AVIRAtea Pharmaceuticals1.8634 of 5 stars$2.92-0.3%$6.00+105.5%-16.2%$232.52MN/A-1.8170VORVor Biopharma3.4083 of 5 stars$39.89+18.6%N/AN/A$230.43MN/A-0.15140Insider TradeHigh Trading VolumeOGIOrganigram Global1.0718 of 5 stars$1.97+16.6%N/A+6.8%$227.04M$117.47M39.41860Gap DownHigh Trading VolumePRQRProQR Therapeutics2.3583 of 5 stars$2.19+3.8%$8.00+265.3%+25.6%$222M$20.46M-4.76180Positive NewsHRTXHeron Therapeutics3.5686 of 5 stars$1.27+5.0%$4.50+254.3%-37.7%$221.81M$149.69M-63.50300Positive NewsTRDAEntrada Therapeutics3.1621 of 5 stars$5.84+0.7%$25.67+339.5%-64.9%$220.62M$79.48M-3.28110Positive NewsCABACabaletta Bio2.2546 of 5 stars$2.38+0.8%$14.50+509.2%-42.7%$215.86MN/A-0.8850 Related Companies and Tools Related Companies Cartesian Therapeutics Competitors Tiziana Life Sciences Competitors Sagimet Biosciences Competitors Atea Pharmaceuticals Competitors Vor Biopharma Competitors Organigram Global Competitors ProQR Therapeutics Competitors Heron Therapeutics Competitors Entrada Therapeutics Competitors Cabaletta Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
